SCHEMBL2592335

SCHEMBL2592335

Cc1ccc(-c2nc3ccc(Br)cc3o2)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.51
NPC1 O15118 12/20 0.50
RAB9A P51151 12/20 0.50
ESR1 P03372 6/20 0.47
ESR2 Q92731 6/20 0.47
SMN1; SMN2 Q16637 9/20 0.46
ALDH1A1 P00352 8/20 0.46
HPGD P15428 8/20 0.46
KDM4E B2RXH2 8/20 0.46
MAPT P10636 5/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
HSD17B10 Q99714 5/20 0.46
USP2 O75604 2/20 0.46
MAPK1 P28482 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HCRTR1 O43613 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14098917 0.84 NPC1 (0.68) GPR119NPC1RAB9AESR1ESR2
SCHEMBL2582851 0.84 NPC1 (0.63) GPR119NPC1RAB9AESR1ESR2
SCHEMBL23387567 0.84 NPC1 (0.59) NPC1RAB9AESR1ESR2SMN1; SMN2
SCHEMBL13533826 0.82 GPR119 (0.54) GPR119NPC1RAB9AESR1ESR2
SCHEMBL2592319 0.81 RAB9A (0.62) GPR119NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4052930 0.79 ESR1 (0.57) NPC1RAB9AESR1ESR2SMN1; SMN2
SCHEMBL4051615 0.78 NPC1 (0.68) GPR119NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL30545875 0.78 NPC1 (0.72) NPC1RAB9AESR1ESR2SMN1; SMN2
SCHEMBL28629954 0.78 NPC1 (0.72) NPC1RAB9AESR1ESR2SMN1; SMN2
SCHEMBL23999977 0.78 NPC1 (0.76) NPC1RAB9AESR1ESR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566864-B1 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-09-03 EP disclosed
US-8772323-B2 Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 US disclosed
US-20130172323-A1 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 US disclosed
EP-2566864-A2 PYRIDAZINONES AS GPR119 AGONISTS Boehringer Ingelheim International GmbH (DE) 2013-03-13 EP disclosed
WO-2011138427-A2 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172323-A1 PYRIDAZINONES AS GPR119 AGONISTS GPR65, GPR119, GPR55 GPR119 2/4885NPC1 2612/4885RAB9A 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.